Abstracts tagged "plasma cells and therapeutic targeting"

Abstract Number: 20 • 2018 ACR/ARHP Annual Meeting
Expression and Functions of the Transcription Factors Ikaros and Aiolos in Sjogren’s Syndrome and Systemic Lupus Erythematosus
Felice Rivellese^1,2, Daniele Mauro¹, Mattia Congia³, Elena Pontarini¹, Peter Schafer⁴, Michele Bombardieri^1,2, Costantino Pitzalis^1,5 and Myles J. Lewis^1,2, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kindgdom, London, United Kingdom, ²Barts Health NHS Trust & Barts and the London School of Medicine & Dentistry, London, United Kingdom, London, United Kingdom, ³Rheumatology and Rheumatology Unit, University Clinic and AOU of Cagliari, Cagliari, Italy, Cagliari, Italy, ⁴Celgene Corporation, Summit, NJ, ⁵Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
Background/Purpose: Polymorphisms of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), which are essential for the maturation, differentiation and survival of B cells, have been…
Abstract Number: 1954 • 2014 ACR/ARHP Annual Meeting
Successfull Long-Term Depletion of Memory Plasma Cells Requires a Combined Depletion of Plasma Cells and Their Precurors in NZB/W Mice
Adriano Taddeo¹, Laleh Khodadadi¹, Qingyu Cheng², Andreas H. Radbruch¹, Falk Hiepe³ and Bimba F. Hoyer², ¹Deutsches Rheumaforschungszentrum, Berlin, Germany, ²Charité University Medicine, Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Germany, Berlin, Germany, ³Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany
Background/Purpose: Autoantibodies contribute significantly to the pathogenesis of systemic lupus erythematosus (SLE). The long-lived plasma cells (LLPC) secreting such autoantibodies are unfortunately refractory to conventional…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].